Elicio Therapeutics (ELTX) Restructuring Costs (2022)

Elicio Therapeutics' (ELTX) quarterly Restructuring Costs came in at $3.1 million in Q4 2022, up 12.48% on a QoQ basis from $2.8 million in Q3 2022.

Elicio Therapeutics (ELTX) Restructuring Costs (2022) Analysis & Trends

Elicio Therapeutics (ELTX) has 1 years of Restructuring Costs data on file, last reported at $3.1 million in Q4 2022.

Quarterly Restructuring Costs changed N/A year-over-year to $3.1 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $5.9 million (changed N/A YoY) and the FY2022 annual result came in at $9.2 million, changed N/A from the prior year.
Restructuring Costs grew to $3.1 million in Q4 2022, from $2.8 million in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $3.1 million in Q4 2022 to a low of $2.8 million in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.29 Bn	131.44 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.31 Bn	78.32 Bn	3.93 Bn
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn
4	Moderna	59.49 Bn	54.36 Bn	52.00 Mn
5	BeOne Medicines	42.02 Bn	36.92 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.79 Bn	27.48 Bn	992.69 Mn
7	BioNTech SE	28.26 Bn	9.87 Bn	668.28 Mn
8	Insmed	27.30 Bn	26.14 Bn	358.27 Mn
9	Royalty Pharma	27.10 Bn	26.26 Bn	-
10	Elicio Therapeutics	59.08 Mn	35.58 Mn	-

Download Data

Date	Value
Dec 31, 2022	3.15 Mn
Sep 30, 2022	2.80 Mn